---
canonical_name: MID-35
alternate_names: Myostatin Inhibitory D-Peptide-35, MID35
canonical_topic: MID-35 for Muscle Growth
short_topic_lc: mid_35_muscle
creation_date: 2026-0913-1227
creator_ai_fullname: Opus 5
ep_keywords: Myostatin Inhibitors, D-Peptides, Peptides
---

# MID-35 for Muscle Growth
<section id="top" markdown="1"></section>
Evidence Review created on 09/13/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5

**Also known as:** Myostatin Inhibitory D-Peptide-35, MID35
  
## Motivation

<!-- Author's note: this Motivation section was written last, after every other section of this review was complete, so that it reflects the full scope of what the evidence does and does not support. -->

MID-35 (myostatin inhibitory D-peptide-35) is a small, laboratory-made protein fragment designed to block myostatin, the signal the body uses to cap how much muscle it will build. Because that cap tightens with age, blocking it has long attracted interest as a way to keep strength and mobility late in life.

Myostatin was identified in the 1990s after cattle and, later, people carrying a broken copy of the gene turned out to be unusually muscular. Large drug companies then spent two decades building antibodies against the pathway, with mixed outcomes. MID-35 belongs to a different and much newer line of work: a mirror-image peptide built to resist breakdown in the body, injected directly into a muscle, and so far tested only in mice.

This review examines what is actually known about MID-35 — the animal findings behind it, the properties that distinguish it from earlier antibody approaches, what the wider record of myostatin blockade in people suggests about its likely effects and hazards, and where the gaps in that record lie.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**
  
## Recommended Reading

High-level material that explains myostatin blockade — the mechanism MID-35 exists to exploit — in enough depth to place this compound in context.

<!-- Search statement: On 2026-09-13 I ran real-time web searches for "MID-35", "myostatin inhibitor peptide", and "<expert name> + myostatin" against each priority platform (foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com, lifespan.io), and searched lifespan.io on-site via d-browser (https://www.lifespan.io/?s=myostatin). Only peterattiamd.com returned substantial myostatin-pathway content. Because MID-35 itself is a preclinical compound with no lay coverage, the remaining slots were filled with narrative reviews that treat the mechanism and therapeutic category in depth; systematic reviews and meta-analyses were excluded from this section by design. -->

- [#370 – AMA #76: Peter evaluates longevity drugs, aspirin for CVD, and strategies to improve muscle mass — proven, promising, fuzzy, noise, or nonsense?](https://peterattiamd.com/ama76/) - Peter Attia

  Attia grades muscle-building interventions (and aspirin for CVD, cardiovascular disease) by evidence strength, closing on myostatin and follistatin (a natural myostatin blocker) biology — the growth-limiting signal MID-35 targets — and why injectable approaches stay impractical.

- [Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies](https://pubmed.ncbi.nlm.nih.gov/35812316/) - Baig et al., 2022

  Narrative review of myostatin structure and the whole inhibitor landscape, including the short peptides carved from myostatin's own precursor region from which MID-35 descends.

- [Myostatin Research: From Molecular Understanding to Clinical Translation for Musculoskeletal and Metabolic Disorders](https://pubmed.ncbi.nlm.nih.gov/42123420/) - Lei et al., 2026

  Current narrative review mapping small molecules, antibodies and gene therapy against myostatin with the translation record of each — context for placing a mouse-stage compound such as MID-35.

- [Myostatin inhibitors in sarcopenia treatment: A comprehensive review of mechanisms, efficacy and future directions](https://pubmed.ncbi.nlm.nih.gov/41460393/) - Samali et al., 2025

  Reviews how myostatin blockade has performed against sarcopenia (age-related muscle loss), weighing mass gains against the repeated failure to move physical performance — the benchmark any new inhibitor must clear.

- [Current and investigational medications for the treatment of sarcopenia](https://pubmed.ncbi.nlm.nih.gov/37348598/) - Rolland et al., 2023

  Places myostatin and activin receptor drugs beside testosterone, growth hormone and other muscle agents, showing mass gains repeatedly failing to translate into function — the central caveat for this class.

Note on priority experts: only Peter Attia has published substantial material on this mechanism. Searches of FoundMyFitness, Huberman Lab, Chris Kresser, Life Extension and Lifespan.io returned no article, episode or lecture that treats myostatin inhibition — let alone MID-35 — in depth, which is expected for a compound that has never entered human testing.
  
## Grokipedia

<!-- Search statement: grokipedia.com was searched on 2026-09-13 for "MID-35" using d-browser (browser_navigate to https://grokipedia.com/search?q=MID-35, then browser_snapshot). The first tier succeeded, so d-fetch, d-proxy-1 and d-proxy-2 were not required. The result set contained only pages matching the numeral 35 (Interstate 35, Navalny 35, .35 Whelen, AMC 35, KiHa 35, Lotus 35, KTDU-35 and similar); no entry on the peptide, on myostatin, or on myostatin inhibitors was returned. -->

No Grokipedia article exists for MID-35. A direct search of grokipedia.com returned only unrelated pages that share the string "35", and no entry covering this peptide or myostatin inhibitory peptides generally.
  
## Examine

<!-- Search statement: examine.com was searched on 2026-09-13 for "MID-35". d-browser (browser_navigate to https://examine.com/search/?q=MID-35) was blocked by a Vercel Security Checkpoint interstitial; d-fetch returned HTTP 429; d-proxy-1 (browser_navigate to the same URL, then browser_snapshot) retrieved the genuine results page, which states "Sorry, there are no search results for MID-35." d-proxy-2 was therefore not needed. -->

No Examine article exists for MID-35. Examine covers dietary supplements and nutrients sold to consumers, and MID-35 is an unapproved research peptide with no consumer supplement form, so its absence is expected.
  
## ConsumerLab

<!-- Search statement: consumerlab.com was searched on 2026-09-13 for "MID-35" using d-browser (browser_navigate to https://www.consumerlab.com/search/?q=MID-35, then browser_snapshot). The first tier succeeded, so d-fetch, d-proxy-1 and d-proxy-2 were not required. The results page returned only product reviews and clinical updates matching the numeral 35 (alginate supplements, basil seeds, folic acid, DEET concentration, oregano oil testing) and no page on this peptide or on myostatin inhibitors. -->

No ConsumerLab article exists for MID-35. ConsumerLab tests commercially sold supplement products, and MID-35 is not sold as a supplement, so its absence is expected.
  
## Systematic Reviews

<!-- Search statement: PubMed was searched on 2026-09-13 via d-pubmed (pubmed_search_articles) for "MID-35", for "(MID-35 OR \"myostatin inhibitory D-peptide\") AND (systematic review OR meta-analysis)", and for "myostatin inhibitor meta-analysis muscle mass randomized" restricted to Systematic Review and Meta-Analysis publication types. The first query returned 19 records, of which only four concern this peptide and all four are primary animal or medicinal-chemistry studies; the second and third returned zero records. -->

No systematic reviews or meta-analyses for MID-35 were found on PubMed as of September 13, 2026.

Both sides of the trade-off are unrepresented: no systematic review or meta-analysis covers the claimed benefit (muscle growth from MID-35) and none covers the principal risk (harm from sustained myostatin blockade), because the compound has never been studied in people.
  
## Mechanism of Action

Myostatin (also called GDF-8, a protein made by muscle that caps its own growth) belongs to the TGF-β superfamily (transforming growth factor beta, a family of signaling proteins). It binds the activin receptor type IIB (ActRIIB) on muscle fibers and activates SMAD2/3 (internal messenger proteins), which suppresses muscle protein synthesis, restrains muscle satellite cells (resident stem cells that repair and enlarge fibers), and raises the muscle-wasting markers MuRF1 and atrogin-1 (proteins that tag muscle protein for disposal).

MID-35 is a 16-amino-acid retro-inverso D-peptide — a mirror-image sequence read backwards — derived from the earlier peptide MIPE-1686. It binds myostatin itself, masking the site where the ligand docks its type I receptor ([Takayama et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35300091/) — from the group that invented MID-35 and holds the interest in it, a conflict covering its entire evidence base).

Its D-amino acids resist the peptidases (enzymes that cut peptides apart) that clear ordinary peptides; it bypasses cytochrome P450 enzymes (the liver's drug-processing system), and no human half-life has been published. In mice, one intramuscular dose produced hypertrophy (growth in muscle size) lasting twelve weeks, implying prolonged residence in the injected muscle, to which distribution appears confined. Selectivity is partial: it also inhibits GDF-11, activin A and TGF-β1 (related signaling proteins), at three- to eight-fold higher concentrations.

Two readings compete. One attributes the growth to myostatin blockade alone; the other, prompted by a rise in sphingosine 1-phosphate (a lipid messenger) three days after dosing, credits satellite-cell activation that needle injury may itself provoke ([Morito et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42312157/)).
  
## Historical Context & Evolution

Myostatin was identified in 1997, when deleting the gene in mice produced animals with roughly double the normal muscle mass ([McPherron et al., 1997](https://pubmed.ncbi.nlm.nih.gov/9139826/)). The same loss of function explained the "double-muscled" Belgian Blue and Piedmontese cattle breeds, and in 2004 a child carrying two inactive copies was described with pronounced muscle bulk and no apparent illness ([Schuelke et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15215484/)). Removing this brake therefore looked like a route to muscle that did not involve androgens (male-hormone drugs).

The first pharmacological attempts were antibodies and receptor traps aimed at muscular dystrophy, each designed and funded by the manufacturer developing it — a conflict of interest that runs through the entire human record for this class. Stamulumab (MYO-029) proved tolerable but produced no functional gain ([Wagner et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18335515/)). The receptor trap ACE-031 showed trends toward higher lean mass, higher bone mineral density and preserved walking distance, but dosing was stopped after nosebleeds and small dilated skin vessels appeared ([Campbell et al., 2017](https://pubmed.ncbi.nlm.nih.gov/27462804/)). Bimagrumab, which blocks the receptor rather than the ligand, cut fat mass and raised lean mass over 48 weeks ([Heymsfield et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33439265/)) and remains in development.

The peptide line ran separately. A Japanese academic group built short inhibitors from myostatin's own precursor region, reaching MIPE-1686, whose breakdown in the body limited it. Rebuilding that sequence as a protease-resistant mirror image produced MID-35 in 2022; delivery and mechanism studies followed. Every published MID-35 result comes from that group.
  
## Expected Benefits

<!-- Search statement: before writing this section I searched PubMed via d-pubmed for "MID-35", "myostatin inhibitory peptide MIPE skeletal muscle", "myostatin inhibitor clinical trials sarcopenia review translation" and "myostatin inhibition resistance exercise training", and ran web searches for "MID-35 peptide muscle growth myostatin" and "myostatin inhibitor peptide muscle". The complete MID-35 literature is four papers (PMID 35300091, 35849084, 36986496, 42312157), all in mice or in vitro. No human exposure to MID-35 is recorded anywhere, so under the evidence-class rule every benefit below caps at Speculative. -->

### High 🟩 🟩 🟩

No benefit reaches High: the evidence class for MID-35 is rodent muscle weight and gene expression, with no human clinical endpoint and no validated clinical surrogate measured in any trial.

### Medium 🟩 🟩

No benefit reaches Medium either: there is no single human trial and no human observational dataset in which MID-35 was administered.

### Low 🟩

### Speculative 🟨

#### Localized Skeletal Muscle Hypertrophy

One shin-muscle injection in mice raised its weight 1.3-fold by day 28 ([30 nmol study](https://pubmed.ncbi.nlm.nih.gov/35300091/)); a 2 nmol dose held the gain 12 weeks ([time-course study](https://pubmed.ncbi.nlm.nih.gov/42312157/)). Transdermal delivery gave 1.25-fold ([delivery study](https://pubmed.ncbi.nlm.nih.gov/36986496/)). Untested in humans.

#### Muscle Satellite Cell Activation and Fiber Regeneration

Three days after dosing, mouse muscle showed raised Pax7, Myod1 and Myog (genes marking muscle stem-cell activation) and more centrally-nucleated fibers, indicating regeneration. Mechanistic animal evidence only ([mouse time-course study](https://pubmed.ncbi.nlm.nih.gov/42312157/)).

#### Reduced Fat Mass and Improved Glucose Handling ⭕️ Not Central to Muscle Growth

Blocking this pathway systemically lowers fat and glycated hemoglobin in people, but MID-35 acts locally and was never tested for either; the basis is mechanistic extrapolation. It bears on body composition ([receptor-blockade trial](https://pubmed.ncbi.nlm.nih.gov/33439265/)).

#### Muscle Strength and Physical Function

In mice with cancer wasting, MID-35 curbed muscle loss and, with anamorelin, raised grip strength and survival ([wasting study](https://pubmed.ncbi.nlm.nih.gov/35849084/)). Untested in humans; human trials of pathway blockers added mass without function ([sarcopenia drug review](https://pubmed.ncbi.nlm.nih.gov/37348598/)).
  
## Benefit-Modifying Factors

- **MSTN genotype (rs1805086, K153R):** carriers of the rarer R allele of MSTN (the gene encoding myostatin itself) show altered muscle power and would begin from a different baseline signal strength, plausibly changing how much a blocker adds ([Santiago et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21283721/)).

- **Baseline myostatin and muscle mass:** the lower the starting myostatin drive and the closer a muscle already is to its ceiling, the less headroom a blocker has. People with high baseline muscle would be expected to gain least.

- **Sex-based differences:** all MID-35 work used male mice. Women carry lower absolute muscle mass and different sex-hormone support for muscle protein synthesis, and no data exist on whether the response differs.

- **Pre-existing health conditions:** conditions that raise myostatin — chronic kidney disease, heart failure, cancer cachexia (wasting driven by illness) — offer more signal to block, whereas denervated or fibrotic muscle may lack the stem cells needed to respond.

- **Age-related considerations:** hypertrophy still occurred in aged mice, but the sphingosine 1-phosphate rise seen in young and adult animals was absent, suggesting the stem-cell arm of the response weakens with age ([Morito et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42312157/)).

- **Training and protein intake:** in mice, myostatin blockade combined with resistance training produced larger gains than blockade alone, and added essential amino acids improved muscle quality ([Jang et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33947024/)).
  
## Potential Risks & Side Effects

<!-- Search statement: before writing this section I searched drug-reference and regulatory-grade sources for a MID-35 safety profile and found none — the compound has no prescribing information, no drugs.com monograph, no Mayo Clinic entry and no regulatory dossier, because it has never been given to a person. I therefore searched PubMed via d-pubmed for the documented harms of the myostatin-pathway class ("ACE-031 Duchenne muscular dystrophy safety", "LY2495655 landogrozumab pancreatic cancer survival", "bimagrumab obesity randomized", "myostatin inhibitors sarcopenia review") and treated those findings as class-level extrapolation, which caps every item below at Speculative. -->

### High 🟥 🟥 🟥

No risk reaches High: the evidence class is animal work plus extrapolation from other molecules, and no documented adverse event in a person given MID-35 exists because no person has been given it.

### Medium 🟥 🟥

No risk reaches Medium either: no single human trial and no human observational dataset covers MID-35.

### Low 🟥

### Speculative 🟨

#### Local Muscle Injury and Injection-Site Reaction

The primary documented route is injection into a target muscle; centrally-nucleated fibers in treated mice indicate tissue damage and repair. No safety endpoint has been reported in any species ([mouse time-course study](https://pubmed.ncbi.nlm.nih.gov/42312157/)).

#### Off-Target Blockade of Related Signaling Proteins

MID-35 also inhibits GDF-11, activin A and TGF-β1 (relatives governing blood formation and tissue patterning) at three- to eight-fold higher concentrations than myostatin ([reporter-assay study](https://pubmed.ncbi.nlm.nih.gov/35300091/)). No animal toxicity study has tested the consequence.

#### Nosebleeds and Dilated Skin Vessels Reported with Broader Pathway Blockade

A receptor trap in Duchenne muscular dystrophy was halted for epistaxis (nosebleeds) and telangiectasias (small dilated skin vessels). That agent blocked more signals than MID-35 does; extrapolation is speculative ([halted receptor-trap trial](https://pubmed.ncbi.nlm.nih.gov/27462804/)).

#### Tendon and Connective Tissue Lagging Muscle Gain

Muscle enlarging faster than its tendon can adapt is a recognized concern with myostatin blockade, drawn from myostatin-deficient animal models. No MID-35 study examined tendon, and no human case exists ([myostatin research review](https://pubmed.ncbi.nlm.nih.gov/42123420/)).

#### Muscle Quality Falling as Mass Rises

Myostatin blockade repeatedly adds muscle mass while lowering strength per unit of mass in rodents ([mouse training study](https://pubmed.ncbi.nlm.nih.gov/33947024/)). MID-35's one grip-strength reading, in wasting mice, gives no force-per-mass figure ([wasting study](https://pubmed.ncbi.nlm.nih.gov/35849084/)).

#### Immune Response to a Synthetic Mirror-Image Peptide

Repeat dosing of a foreign sequence can raise antibodies that neutralize it or cause local reactions. Immunogenicity testing for MID-35 has not been published; the concern is theoretical ([myostatin inhibitor review](https://pubmed.ncbi.nlm.nih.gov/35812316/)).

#### Worse Outcomes if an Undetected Cancer Is Present

A myostatin antibody shortened survival in pancreatic cancer, an unexplained signal. Whether a locally injected peptide carries the same hazard is untested; the basis is a single trial of a different agent ([pancreatic cancer trial](https://pubmed.ncbi.nlm.nih.gov/30051975/)).

#### Exposure to Impure or Misidentified Material

MID-35 is sold only as a research chemical: no official quality standard, no batch release testing, no sterility requirement. Contaminant and identity risk is inferred from the unregulated peptide market, not measured for this compound.
  
## Risk-Modifying Factors

- **MSTN and ACTN3 genotype:** neither MSTN (the gene encoding myostatin) nor ACTN3 (a fast-fiber structural protein removed by the R577X variant) has been tested as a modifier of harm from myostatin blockade, so any influence is unquantified.

- **Baseline biomarker levels:** low platelet count, a raised international normalized ratio, or already-elevated creatine kinase (an enzyme leaking from damaged muscle) would each amplify the bleeding and muscle-damage risk of repeated intramuscular injection.

- **Sex-based differences:** no sex comparison exists for MID-35 or for peptide myostatin blockers. Women show a smaller absolute lean-mass response to receptor blockade, which may also mean smaller absolute exposure-related harm.

- **Pre-existing health conditions:** bleeding disorders, anticoagulation, hereditary hemorrhagic telangiectasia, active cancer and severe kidney impairment each map onto a documented class hazard or onto impaired peptide clearance.

- **Age-related considerations:** older muscle has fewer satellite cells and slower repair, so injection trauma resolves more slowly; thinner skin and more fragile capillaries also raise local bruising risk.
  
## Key Interactions & Contraindications

- **Anticoagulants and antiplatelets (blood-thinning drugs; warfarin, apixaban, rivaroxaban, clopidogrel):** caution — intramuscular injection into anticoagulated muscle can cause deep hematoma (a trapped pocket of blood) and compartment pressure. Mitigation: avoid the intramuscular route entirely while anticoagulated.

- **NSAIDs (non-steroidal anti-inflammatory drugs; ibuprofen, naproxen, high-dose aspirin):** caution — added bleeding at the injection site, and blunting of the satellite-cell response that the compound depends on. Mitigation: separate use by at least 48 hours around dosing.

- **Glucocorticoids (steroid anti-inflammatory drugs; prednisone, dexamethasone):** monitor — these raise myostatin expression and drive muscle breakdown, directly opposing the intervention. Mitigation: none reliable; expect reduced or absent effect during systemic steroid courses.

- **GLP-1 receptor agonists (glucagon-like peptide-1 drugs; semaglutide, tirzepatide):** monitor — these cause lean-mass loss during weight reduction, which myostatin blockade is being trialed to offset. Consequence is uncertain interaction, not harm; combined use is under formal study only.

- **Androgens and selective androgen receptor modulators (male-hormone drugs; testosterone, enobosarm):** caution — additive anabolic signaling with additive load on tendon and connective tissue. Mitigation: do not stack while tendon adaptation is unmonitored.

- **Supplements with additive or overlapping action (creatine monohydrate, HMB, leucine-rich essential amino acids, epicatechin, follistatin-containing egg-yolk extracts):** caution — epicatechin and follistatin products are sold as myostatin blockers, HMB (a leucine breakdown product) as muscle-sparing, so effects may be additive and unquantifiable.

- **Other interventions (resistance training, blood-flow-restriction training):** caution — potentiating in mice, where training amplifies myostatin blockade; the consequence is tendon and joint strain as muscle outpaces them. Mitigation: progress load gradually.

**Populations who should avoid MID-35:**

- Anyone outside a formal research setting — the compound has no approval in any jurisdiction and no established human dose.
- Active or recently treated malignancy (within 5 years), given the survival signal seen with myostatin antibody therapy in advanced cancer.
- Pregnancy and lactation — no reproductive toxicity data exist in any species.
- Bleeding disorders, or anticoagulation with an international normalized ratio above 3.0.
- Hereditary hemorrhagic telangiectasia or any known vascular malformation syndrome.
- Severe kidney impairment (estimated glomerular filtration rate below 30 mL/min/1.73 m²), which slows peptide clearance.
- Known tendon pathology, or recent tendon rupture or repair (within 12 months).
  
## Risk Mitigation Strategies

- **Confine use to a research protocol:** the compound has no human dose, no toxicity dossier and no approval, which is the only reliable mitigation for the unknown-exposure risk listed above.

- **Cancer screening before any exposure:** age-appropriate screening plus imaging of any suspicious finding, to mitigate the survival signal seen when myostatin was blocked in people with undetected or advanced malignancy.

- **Stop all bleeding-risk agents around dosing:** no NSAIDs for 48 hours either side, no injection while anticoagulated, mitigating hematoma and the nosebleed and skin-vessel signals seen with broader pathway blockade.

- **Aseptic single-use injection technique:** sterile single-use needles, skin preparation with 70% isopropyl alcohol, fresh site each time, mitigating the infection and local-injury risk of repeated intramuscular dosing.

- **Independent identity and purity testing:** third-party mass spectrometry and purity above 98% on every batch, mitigating the contaminant and misidentification risk of research-chemical sourcing.

- **Progress tendon loading before muscle loading:** 6–8 weeks of heavy slow resistance work at 3 sessions weekly before adding load, mitigating tendon strain when muscle enlarges faster than its attachment adapts.

- **Baseline and 4-weekly creatine kinase:** a value above 3 times the upper reference limit signals excessive muscle damage from injection trauma and warrants stopping.
  
## Therapeutic Protocol

- **No human protocol exists:** no clinic, practitioner or guideline uses MID-35. Everything below describes published laboratory regimens, not a human dosing scheme, and no conversion to a human dose has been attempted.

- **Direct intramuscular regimen:** 30 nmol of MID-35 injected once into the shin muscle of young mice raised muscle weight about 1.3-fold by day 28 ([Takayama et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35300091/)); 2 nmol sufficed in adult mice ([Morito et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42312157/)).

- **Transdermal iontophoresis regimen:** the alternative approach drives the peptide through skin into the underlying muscle using weak electrical current, raising muscle mass 1.25-fold without a needle ([Michiue et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36986496/)).

- **Competing approaches, no default:** local peptide delivery is one of three routes under study; the others are systemic receptor antibodies and gene therapy. Each has different reach, duration and hazard, and none has shown functional superiority.

- **Groups that originated each approach:** the peptide series came from the medicinal chemistry group at Tokyo University of Pharmacy and Life Sciences with Fujita Health University; the iontophoresis delivery route came from Tokushima University.

- **Best time of day:** unstudied. No circadian dependence has been tested for this compound, and mouse dosing was not time-controlled, so no timing recommendation can be derived from the literature.

- **Half-life in the body:** no human or mouse half-life has been published. The mirror-image backbone resists peptide-cutting enzymes, and one dose sustained muscle growth for 12 weeks, implying long local residence.

- **Single versus split dosing:** all published work used a single injection per muscle. Whether repeated or divided dosing adds benefit, or merely adds injection trauma, has not been tested.

- **Genetic polymorphisms:** MSTN rs1805086 alters myostatin itself and ACTN3 R577X alters fast-fiber composition. Neither has been examined as a dose modifier, so genotype cannot currently inform any regimen.

- **Sex-based differences:** all reported experiments used male mice. No dose, response or safety comparison by sex exists for MID-35 or for any peptide myostatin inhibitor.

- **Age-related considerations:** aged mice grew muscle but lacked the lipid-messenger response seen in younger animals, implying the regenerative arm weakens with age and that older tissue may need different exposure.

- **Baseline biomarkers influencing response:** baseline muscle mass, serum myostatin and creatine kinase would plausibly shape both response size and injury risk, but no study has stratified by any of them.

- **Pre-existing conditions influencing response:** conditions raising myostatin (kidney disease, heart failure, cancer wasting) offer more signal to block; fibrotic or denervated muscle lacks the stem cells the response depends on.
  
## Discontinuation & Cycling

- **Intended duration is undefined:** no human course length exists. In mice a single dose produced growth lasting 12 weeks, so the compound behaves as an episodic rather than continuous intervention.

- **Withdrawal effects:** none reported. Myostatin signaling is expected to return as the peptide clears, with muscle gain reversing toward baseline; no study followed animals past the hypertrophic phase to confirm.

- **Tapering:** not applicable to a single-injection design. There is no receptor downregulation or dependence mechanism described that would require gradual withdrawal.

- **Cycling:** unstudied. The 12-week persistence of effect after one dose implies any repeat interval shorter than that adds injection trauma without adding signal, but no dosing-interval experiment has been run.
  
## Sourcing and Quality

- **No pharmaceutical-grade source exists:** MID-35 is not manufactured to good manufacturing practice standards, is not stocked by any compounding pharmacy, and is available only through research-chemical catalogues that sell for laboratory use.

- **What to look for:** a certificate of analysis giving identity by mass spectrometry, purity above 98% by high-performance liquid chromatography, stated counter-ion and net peptide content, plus endotoxin and sterility testing.

- **Third-party testing is essential:** supplier certificates for research peptides are frequently the synthesis house's own. Independent re-testing of identity and purity is the only meaningful check on what is in the vial.

- **Formulation considerations:** supplied as freeze-dried powder requiring reconstitution in sterile water or bacteriostatic saline, refrigerated storage after reconstitution, and protection from repeated freeze-thaw cycles that degrade peptides.

- **Reputable brands:** none can be named. No supplier has an independent quality reputation for this compound, and listings appear only in bulk research-chemical directories rather than from established pharmaceutical manufacturers.
  
## Practical Considerations

- **Time to effect:** in mice, gene-level changes appeared within 3 days but measurable muscle weight gain took 14 days, peaking around 28 days and persisting 12 weeks ([Morito et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42312157/)).

- **Common pitfalls:** treating mouse nanomole doses as convertible to human doses; assuming a locally injected peptide produces whole-body effects; and expecting strength gains, which only one mouse wasting model has ever measured.

- **Regulatory status:** not approved anywhere, not a dietary supplement, and not available on prescription. Myostatin inhibitors are also prohibited in sport by the World Anti-Doping Agency, an enforcement body rather than an evaluator of benefit.

- **Cost and accessibility:** research-grade milligram quantities are expensive relative to their unknown value, and no insurer or health system covers any of it. Availability depends entirely on unregulated laboratory supply channels.

- **Cost against the alternative:** resistance training with adequate protein achieves muscle growth at negligible cost, so payers and health systems have a structural incentive to favor it and little incentive to fund trials of expensive muscle pharmacology.
  
## Interaction with Foundational Habits

- **Sleep:** no direct interaction is described — the compound acts locally on a growth-suppressing signal, not on arousal or circadian pathways. Indirectly, muscle repair and satellite-cell activity depend on sleep, so short sleep would be expected to blunt the regenerative arm of the response.

- **Nutrition:** potentiating and direct. Blocking myostatin raises muscle protein synthesis, which requires amino acid substrate to express. In mice, added essential amino acids improved muscle quality alongside myostatin blockade ([Jang et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33947024/)); adequate daily protein is the practical requirement.

- **Exercise:** potentiating and direct. Resistance training lowers myostatin expression by a separate route and amplified the mass and strength gains from myostatin blockade in mice. Practical consideration: train the injected muscle, but build tendon loading first so attachment tissue keeps pace with muscle growth.

- **Stress management:** indirect and blunting. Sustained cortisol elevation raises myostatin expression and drives muscle protein breakdown, working directly against the intervention. No study has measured cortisol alongside MID-35, so the interaction is inferred from glucocorticoid biology rather than observed.
  
## Monitoring Protocol & Defining Success

No validated monitoring protocol exists, because no human has been dosed. What follows is the panel that the identified hazards and the mechanism imply, not a scheme drawn from clinical practice. Before any exposure, a baseline set establishes muscle status and the safety margins that the injection route and the class signals put at issue: body composition, muscle damage, inflammation, liver and kidney handling, blood counts, clotting and glucose control. Because the compound acts locally and slowly, success and harm both declare themselves over weeks rather than days. A workable cadence repeats the safety subset at 2 weeks and 4 weeks after first exposure, then every 3 months while use continues, with body composition reassessed at 3 and 6 months and the full panel annually thereafter.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Appendicular lean mass index (DEXA) | Men ≥ 7.5 kg/m²; women ≥ 6.0 kg/m² | The primary success measure — regional muscle mass | DEXA is dual-energy X-ray absorptiometry, a scan separating lean, fat and bone. Conventional sarcopenia cut-offs sit lower (7.0 and 5.5 kg/m²). Same machine each time; hydrate consistently |
| Creatine kinase (CK) | 40–200 U/L | Detects muscle fiber damage from injection trauma | CK is an enzyme released when muscle fibers break. Conventional upper limits reach 300–400 U/L. Avoid testing within 72 hours of hard training, which raises it independently |
| High-sensitivity C-reactive protein (hs-CRP) | < 0.5 mg/L | Flags local or systemic inflammatory response to repeated injection | hs-CRP is a general inflammation marker. Conventional "low risk" is < 1.0 mg/L. Retest after any infection resolves; pair with CK to separate muscle damage from systemic inflammation |
| Serum myostatin (GDF-8) | No established target; track change from the individual's own baseline | The only direct read on whether the signal is actually being blocked | GDF-8 assays are not standardized between laboratories, so absolute values are not comparable. Use one laboratory throughout; fasting is not required |
| Estimated glomerular filtration rate (eGFR) | > 90 mL/min/1.73 m² | Peptide clearance depends on kidney function | eGFR estimates how fast kidneys filter blood. Conventional normal starts at 60. Creatine supplementation and high muscle mass both raise creatinine and can understate true eGFR; cystatin C resolves this |
| Alanine aminotransferase (ALT) | Men 10–30 U/L; women 8–25 U/L | Baseline liver status before exposure to an unstudied compound | ALT is a liver enzyme released when liver cells are stressed. Conventional upper limits reach 40–55 U/L, well above the functional target. Fast 8 hours; avoid alcohol for 72 hours |
| Complete blood count with platelets (CBC) | Platelets 175–250 ×10⁹/L; hemoglobin 13.5–15.0 g/dL (men), 12.5–14.5 (women) | Bleeding margin for intramuscular injection, and a check on the class bleeding signal | CBC counts red cells, white cells and platelets. Conventional platelet range extends to 150–400. Recheck if bruising or nosebleeds appear |
| Glycated hemoglobin (HbA1c) | 4.8–5.3% | Myostatin-pathway blockade shifts glucose handling in human trials | HbA1c reflects average blood glucose over about 3 months. Conventional "normal" extends to 5.6%. Unreliable with anemia or recent blood loss; pair with fasting insulin |

Qualitative markers worth tracking alongside the laboratory panel:

- Injection-site soreness, swelling, warmth or persistent lump, and how quickly each resolves
- Girth of the treated limb measured at a fixed landmark, weekly
- Performance in a fixed loaded movement — repetitions at a set weight, held constant
- Tendon or joint discomfort during or after loading, which is the earliest sign that muscle is outpacing its attachment
- Unexplained bruising, nosebleeds or new small red marks on the skin
- Energy, sleep quality and recovery between training sessions
  
## Emerging Research

- **No MID-35 trial is registered:** a ClinicalTrials.gov search returned no study of MID-35 or of any myostatin inhibitory peptide, so the compound's future depends on preclinical work and on what the antibody trials below establish about the mechanism.

- **Bimagrumab with tirzepatide in obesity:** phase 2, 252 participants, testing whether receptor blockade preserves lean mass during weight loss; primary endpoint is percent change in body weight ([NCT06643728](https://clinicaltrials.gov/study/NCT06643728)).

- **Trevogrumab and garetosmab with semaglutide:** phase 2, 1,005 participants, with percent change in total lean mass and total fat mass as co-primary endpoints — the largest test yet of whether blocking this pathway protects muscle ([NCT06299098](https://clinicaltrials.gov/study/NCT06299098)).

- **Bimagrumab and tirzepatide on body composition and bone:** phase 2, 63 participants, primary endpoint kilograms of lean mass by scan, with bone and insulin sensitivity also measured ([NCT05933499](https://clinicaltrials.gov/study/NCT05933499)).

- **Apitegromab in facioscapulohumeral muscular dystrophy (a hereditary muscle-wasting disease):** phase 2, 60 participants, placebo-controlled, testing a myostatin-selective antibody against an inherited cause of muscle loss ([NCT07435129](https://clinicaltrials.gov/study/NCT07435129)).

- **Sphingolipid signaling as a new lever:** the finding that sphingosine 1-phosphate rises after MID-35 dosing in young but not aged mice opens an area that could explain, or undercut, the durability of the response ([Morito et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42312157/)).

- **Longevity signal that would strengthen the case:** mice with one working myostatin copy resisted age-related loss of muscle mass and contractility and showed about 15% greater maximum lifespan ([Mendias et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25808276/)).

- **Evidence that would weaken the case:** repeated failure of mass gains to translate into physical performance across this drug class remains the strongest argument against pursuing it ([Rolland et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37348598/)).
  
## Conclusion

MID-35 is a small, laboratory-made protein fragment built to block myostatin, the body's own brake on muscle growth. Its design — a mirror-image sequence that ordinary body enzymes cannot easily break apart — is what sets it apart from the antibodies that came before, and it is the reason a single injection into a mouse muscle kept that muscle larger for months.

That is also the whole of what is known. Every finding comes from mice, from the laboratory that invented the compound and holds an interest in its development, and the wider human record for blocking this brake is mixed: bigger muscles have reliably followed, greater strength and better function have not, and one agent in the class was stopped for bleeding signs while another was linked to worse survival in advanced cancer. None of those agents is MID-35, so neither their promise nor their harm transfers cleanly.

For someone willing to act ahead of the evidence, the honest picture is a compound with a coherent idea behind it, one clear animal result, no human exposure at all, no approved source, and no way to know what a dose in a person would do. The muscle-growth case rests on animal data alone; the safety case rests on nothing at all.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**